2022
Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials
Moura F, Wiviott S, Chertow G, Dwyer J, Gause-Nilsson I, Johansson P, Langkilde A, McMurray J, Mosenzon O, Raz I, Rossing P, Wheeler D, Sabatine M, Heerspink H. Effects of dapagliflozin on cardiovascular and kidney events by baseline eGFR and UACR in patients with type 2 diabetes mellitus: a patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials. European Heart Journal 2022, 43: ehac544.2407. DOI: 10.1093/eurheartj/ehac544.2407.Peer-Reviewed Original ResearchUrinary albumin:creatinine ratioEffects of dapagliflozinSodium-glucose co-transporter 2Kidney eventsType 2 diabetes mellitusDAPA-CKD trialKidney endpointsBaseline eGFRAbsolute rate differenceDAPA-CKDKidney functionHigh urinary albumin:creatinine ratioPatient yearsPooled analysisPatients type 2 diabetes mellitusCardiovascular deathSubgroups of baseline eGFRPatient-level pooled analysisAlbumin:creatinine ratioLevel of kidney functionFollow-up timeCategories of eGFRBaseline kidney functionHigh cardiovascular riskAbsolute risk reduction
2021
Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis
Moura F, Itamar R, Cahn A, Goodrich E, Bhatt D, Leiter L, WILDING J, Gause-nilsson I, Mosenzon O, Sabatine M, Wiviott S. Abstract 13182: Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis. Circulation 2021, 144: a13182-a13182. DOI: 10.1161/circ.144.suppl_1.13182.Peer-Reviewed Original ResearchHDL-CMetabolic syndromeProgression to MetSAssociation of MetSClassification of MetSPrevalence of MetSHDL-C <Prediction of CV deathRandomized to dapagliflozinComponents of MetSPresence of MetSEffects of dapagliflozinLow HDL-CType 2 diabetes mellitusFollow-up visitAssociated with outcomeType 2 diabetesIDF criteriaBaseline characteristicsCV deathSGLT2 inhibitorsDapagliflozin armHeart failureSub-analysisElevated BP